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he identiﬁcation of molecular motors that modulate
the neuronal cytoskeleton has been elusive. Here,
we show that a molecular motor protein, myosin Va,
is present in high proportions in the cytoskeleton of mouse
CNS and peripheral nerves. Immunoelectron microscopy,
coimmunoprecipitation, and blot overlay analyses demon-
strate that myosin Va in axons associates with neuroﬁlaments,
and that the NF-L subunit is its major ligand. A physiological
association is indicated by observations that the level of
myosin Va is reduced in axons of NF-L–null mice lacking
neuroﬁlaments and increased in mice overexpressing NF-L,
but unchanged in NF-H–null mice. In vivo pulse-labeled
myosin Va advances along axons at slow transport rates
T
 
overlapping with those of neuroﬁlament proteins and actin,
both of which coimmunoprecipitate with myosin Va. Elimi-
nating  neuroﬁlaments from mice selectively accelerates
myosin Va translocation and redistributes myosin Va to
the actin-rich subaxolemma and membranous organelles.
 
Finally, peripheral axons of 
 
dilute-lethal
 
 mice, lacking
functional myosin Va, display selectively increased neuro-
ﬁlament  number and levels of neuroﬁlament proteins
without altering axon caliber. These results identify myosin
Va as a neuroﬁlament-associated protein, and show that this
association is essential to establish the normal distribution,
axonal transport, and content of myosin Va, and the proper
numbers of neuroﬁlaments in axons.
 
Introduction
 
The myosin Va family of nonmuscle myosin genes includes
the 
 
dilute
 
 gene from mouse, the 
 
myr6
 
 gene from rat, the
 
MYO2
 
 and 
 
MYO4
 
 genes from 
 
Saccharomyces cerevisiae
 
, the
brain 
 
myosin Va
 
 gene from chicken, the 
 
Drosophila
 
 
 
myosin V
 
gene, and the 
 
myosin Va
 
 gene from human (Berg et al.,
2001). The protein products of these genes consist of a globular
 
head domain sharing 
 
 
 
40% homology with the head domain
of myosin II, followed by a myosin I–like neck domain
containing six IQ motifs that bind four calmodulin light
chains and two light chains (Espreafico et al., 1992). The
central stalk-like region contains a myosin II–like 
 
 
 
 helical
coiled-coil domain and a second globular domain of unique
amino acid sequence. At least three isoforms of myosin V exist:
Va (Mercer et al., 1991), Vb (Espreafico et al., 1992), and
Vc (Rodriguez and Cheney, 2002). The distinctive functions
of these differentially expressed isoforms are unknown. Myosin
Va is the specific focus of our studies.
Proteins of the myosin V family serve as molecular motors
to transport diverse molecules. Analyses of the 
 
MYO2
 
 gene
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implicate yeast myosin V in the assembly and transport of
actin, the translocation of specific proteins to sites of polar-
ized growth, and the transport of vesicles (Santos and Sny-
der, 1997). The yeast 
 
MYO4
 
 gene product transports com-
ponents necessary for regulating gene expression and targets
mRNA molecules to sites of polarized growth (Bobola et al.,
1996). In rat and chick neuronal tissue, myosin Va mediates
actin-dependent movement of synaptic vesicles and ER
(Tabb et al., 1998), and supports filopodial extension in
growth cones (Wang and Jay, 1997).
Myosin Va protein in brain is highly expressed (Cheney et
al., 1993) and broadly distributed regionally (Mercer et al.,
1991; Espreafico et al., 1992), with prominent localizations in
growth cones and neurites of cultured neurons, astrocyte pro-
cesses (Espindola et al., 1992), and axons of several sensory or-
gans (Hasson et al., 1997). Additionally, myosin Va has been
reported to immunolocalize to the intermediate filament (IF)*
compartment in a variety of cultured cell types (Engle and
Kennett, 1994). Although these findings document that myo-
sin Va is a significant component of CNS neurons and sen-
sory organs, its neural functions are still poorly defined.
Mutations in the mouse myosin Va gene, 
 
dilute
 
, cause not
only defective melanosome movement but also profound
neurological symptoms, including a convulsive disorder that
results in death by 3–4 wk of age (Searle, 1952). Mutations
in the human 
 
myosin Va
 
 gene cause Griscelli’s disease, a
childhood disease characterized by pronounced hypopig-
mentation and a convulsive disorder that leads to premature
death (Pastural et al., 1997). A similar phenotype is associ-
ated with mutations of the ashen locus harboring the
Rab27a gene (Menasche et al., 2000), which regulates myo-
sin Va recruitment to melanosomes (Wu et al., 2001). Some
features of the 
 
dilute
 
 phenotype also result from the flailer
mutation, which originates from germ line exon shuffling
between the guanine nucleotide binding protein 
 
 
 
 5 and
myosin Va genes, leading to the synthesis of a mutant hybrid
protein that competes with wild-type myosin Va (Jones et
al., 2000). These phenotypes clearly underscore the impor-
tance of myosin Va for normal neurological function.
In view of the importance of myosin Va in brain and its
possible association with IFs (Engle and Kennett, 1994), we
investigated whether myosin Va interacts with neurofilaments
and how it influences the properties of neurofilaments in neu-
rons. Neurofilaments predominate in axons and, to a lesser
extent, in dendrites and perikarya of the nervous system where
they modulate the polar shape and size of the neuron (Nixon
and Shea, 1992). Unlike other classes of IFs, neurofilament
 
proteins are heteropolymers formed from three distinct sub-
units with apparent molecular masses of 200 kD (NF-H), 150
kD (NF-M), and 70 kD (NF-L) on SDS–polyacrylamide
gels. In some axons, neurofilaments form a three-dimensional
network with microtubules and actin filaments, mediated by
one or more members of a family of cross-linking proteins
(Svitkina et al., 1996; Yang et al., 1996). How the organiza-
tion of this network is achieved in axons is not known.
Neurofilaments, microtubules, and microfilaments, as well
as their associated proteins, are transported from the peri-
karyon at speeds of 0.1–2.0 mm/d, collectively referred to
as the slow phase of axonal transport. This range of rates is
distinct from that of fast axonal transport, which carries
mainly vesicular constituents by a microtubule-dependent
mechanism powered by kinesin in the anterograde direction
(Hirokawa et al., 1991) and by dynein in the retrograde di-
rection (Schnapp and Reese, 1989). It remains controversial
as to whether different filamentous cytoskeletal structures are
transported exclusively as polymers, subunits/oligomers, or in
both forms under different conditions (Hirokawa et al.,
1997; Wang et al., 2000; Yabe et al., 2001). Short-range
transport mechanisms also mediate restricted longitudinal or
lateral movement of organelles within a specific compartment
of the neuron. Roles for myosin Va in this form of transport
have been suggested (Huang et al., 1999); however, the molec-
ular mechanisms responsible for the movements of cytoskeleton
components within axons are poorly understood.
In the study presented here, we establish by multiple crite-
ria that the neurofilament is a major ligand for myosin Va in
mouse central and peripheral nervous tissue. We demon-
strate that myosin Va binds selectively to the NF-L subunit
of the filament, and that myosin Va content, transport, and
distribution in axons are regulated in vivo, in part, by levels
of NF-L. Our further observations show that myosin Va
moves in the slow phase of axonal transport, prominently as-
sociates with neurofilaments, and alters neurofilament den-
sity selectively when deleted in 
 
dilute
 
-
 
lethal
 
 (
 
dl
 
) mice, sug-
gesting that myosin Va plays a role in the behavior of
neuronal cytoskeletal elements in addition to its well-recog-
nized role in translocating membranous organelles.
 
Results
 
Myosin Va is abundant in 
neurofilament-enriched cytoskeletons
 
An affinity-purified polyclonal antisera against the carboxy-ter-
minal end of myosin Va (Evans et al., 1997) detected a single
Figure 1. Distribution of myosin Va 
in mouse nervous tissues. (A) Spinal 
cord (SC), sciatic nerve (SN), and optic 
nerve (ON) extracts were immunoblotted 
with myosin Va polyclonal antibody. 
(B) Myosin Va is abundant in the 
Triton-insoluble cytoskeletal fraction. 
Equal amounts of Triton-insoluble (P) 
and -soluble fractions (S) were 
immunoblotted with antibodies 
indicated. (C) Myosin Va is absent in 
Triton-insoluble (Cytoskel) and soluble fractions of spinal cord from homozygous dilute (DL) mouse but not from control mice (C). 
 -Tub,  -tubulin; KHC, kinesin heavy chain. 
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band of the expected apparent molecular mass (190 kD) in im-
munoblots of protein from spinal cord, optic, and sciatic nerves
(Fig. 1 A). The same protein was identified with a second affin-
ity-purified rabbit polyclonal antiserum raised to the amino-
terminal domain of myosin Va (unpublished data). Quantita-
tive immunoblot analysis of total protein extracts from the
nervous tissues of the mouse revealed that myosin Va levels are
more than twofold higher in the spinal cord than in optic or
sciatic nerves (Fig. 1, A and B; Table I). The major proportion
of myosin Va (55–67%) immunoreactivity in each of these tis-
sues was associated with the Triton-insoluble cytoskeleton (Fig.
1 B; Table II). By comparison, kinesin heavy chain, another
motor protein, was detected only in Triton-soluble fractions
(Fig. 1 B). The absence of myosin Va immunoreactive protein
in spinal cord fractions from homozygous 
 
dl
 
 mice carrying a
mutation in the myosin Va gene (Fig. 1 C) established the
specificity of the affinity-purified polyclonal myosin Va anti-
body and confirmed the identity of the cytoskeleton-associated
190-kD protein from normal mice as myosin Va. For compari-
son with myosin Va, a known myosin Va ligand (actin) and
NF-L were also analyzed by quantitative Western blot on the
same tissue fractions. The proportions of actin were roughly
comparable in Triton-soluble and Triton-insoluble fractions of
the brain and spinal cord. However, in the optic and sciatic
nerves, cytoskeletal fractions contained only a third of the total
actin, but 55–61% of the total myosin Va (Table II).
 
Myosin Va colocalizes with neurofilaments in axons
 
Myosin Va immunoreactivity was broadly distributed in
neurons within the mouse central and peripheral nervous
systems (Fig. 2), as previously noted. Purkinje cells and their
elaborate dendritic arborizations were well immunolabeled,
as previously shown (Bridgman, 1999) (Fig. 2 A), and other
 
Table I. 
 
Relative levels of myosin Va in neuronal tissues
Myosin Va
 
Brain 100
Spinal cord 38.4 
 
 
 
 5.7
Sciatic nerve 9.6 
 
 
 
 3.21
Optic nerve 15.5 
 
 
 
 5.14
Myosin Va is more abundant in CNS tissues than in the PNS. Equal amounts
of total protein from spinal cord, sciatic nerve, and optic nerve were
immunoblotted with myosin Va polyclonal antibody. Immunoreactive
protein bands were quantified using a BioImage whole band analyzer
(Kodak) after ECL detection. Each value is a mean 
 
 
 
 SD from three
experiments.
Table II. 
 
Relative content of myosin Va, NF-L, and actin in Triton-soluble and cytoskeletal-associated fractions of brain, spinal cord, sciatic 
nerve, and optic nerve
Myosin Va NF-L Actin
Cytoskeletal Soluble Cytoskeletal Soluble Cytoskeletal Soluble
 
Brain 67 
 
 
 
 5.8 33 
 
 
 
 5.8 100 0 57.4 
 
 
 
 3.8 42.6 
 
 
 
 3.8
Spinal cord 55 
 
 
 
 7.1 45 
 
 
 
 7.1 75 
 
 
 
 14.1 25 
 
 
 
 14.1 49.1 
 
 
 
 8.7 50.9 
 
 
 
 8.7
Sciatic nerve 61 
 
 
 
 1.2 39 
 
 
 
 1.2 85 
 
 
 
 5.3 15 
 
 
 
 5.3 35.0 
 
 
 
 7.6 65.0 
 
 
 
 7.6
Optic nerve 55 
 
 
 
 0.4 45 
 
 
 
 0.4 100 0 37.5 
 
 
 
 6.3 62.5 
 
 
 
 6.3
Values are percent of total content in the given tissue. Equal amounts of protein from brain, spinal cord, sciatic nerves, and optic nerve were immunoblotted
with myosin Va polyclonal antibody (pMyo Va), NF-L (NR-4), or actin (A-2066; Sigma-Aldrich) antibody (Kayalar et al., 1996). Immunoreactivities of the
protein bands were quantified using a BioImage whole band analyzer (Kodak) after ECL detection. Each value is an average of three experiments (
 
 
 
SD).
 
neuronal populations were strongly immunoreactive (Fig. 2
A, inset). Axons in spinal cord (Fig. 2 B) and sciatic nerve fi-
bers (Fig. 2 C) were also well labeled. By contrast, immu-
noreactive myosin Va was absent in the corresponding ner-
vous tissue regions of 
 
dl
 
 mice (unpublished data).
Ultrastructural inspection of immunogold-labeled sections
of mouse optic axons revealed that myosin Va immunolabel-
ing in axons is most abundant in association with neurofila-
ments (Fig. 2, D, F, and G). In some cases, trains of anti–
myosin Va gold particles traced the outline of a single
neurofilament (Fig. 2, F and G). Sections from optic nerves of
21-d-old 
 
dl
 
 mice (Fig. 2 E) showed 
 
 
 
6% of the total gold la-
beling seen in age-matched control mice (Fig. 2 D). Immu-
noreactivity was notably absent from microtubules and my-
elin (Fig. 2, D–G, arrowheads). To assess the relative
distribution of immunoreactive myosin Va, we counted gold
particles on, or immediately adjacent to, specific cellular struc-
tures. In 25 micrographs of immunolabeled optic axons, the
number of gold particles associated with neurofilaments was
approximately fourfold greater than that associated with ve-
sicular organelles and the subaxolemmal compartment. My-
osin Va immunoreactivity was also associated with structures
previously identified to be sites of myosin Va localization
(Bridgman, 1999), including the subaxolemmal membrane
(unpublished data), smooth ER (Fig. 2 H), mitochondria
(Fig. 2 J), and small, membrane-bound vesicles within nerve
terminals or preterminal axon swellings (Fig. 2 I).
 
Myosin Va associates only with the NF-L subunit 
of neurofilaments
 
Because neurofilaments are heteropolymers consisting of three
subunits, NF-H, NF-M, and NF-L, we used a blot overlay
analysis to investigate which of the neurofilament subunits
bind to myosin Va. Purified neurofilament subunits were sep-
arated on SDS–polyacrylamide gels and blotted onto nitrocel-
lulose membranes, which were then incubated in solutions
containing decreasing concentrations of myosin Va fused with
 
 
 
-galactosidase (Fig. 3 A, lanes 2–5). As a control, purified
 
 
 
-galactosidase protein was incubated with immobilized neu-
rofilament proteins in a concentration equal to the highest
concentration of myosin Va–
 
 
 
-gal fusion protein used (Fig. 3
A, lane 6). Bound myosin Va–
 
 
 
-gal or 
 
 
 
-galactosidase alone
was detected by Western blot analysis using an anti–
 
 
 
-galac-
tosidase antibody. Fig. 3 A demonstrates that myosin Va
bound to the NF-L subunit in a concentration-dependent
manner, but did not bind to NF-M or NF-H. 
 
 
 
-Galactosidase 
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alone did not bind (Fig. 4 A, lane 6), indicating that the asso-
ciation of myosin Va–
 
 
 
-gal fusion protein with NF-L is due
to the myosin Va portion of the fusion protein.
 
Myosin Va fusion protein coimmunoprecipitates 
with NF-L fusion protein from bacterial extracts
 
To confirm the specificity of the association between myosin
Va and the NF-L subunit, we expressed a cloned myosin
Va–
 
 
 
-galactosidase fusion protein (myosin Va–FP) or a
cloned NF-L–c-Myc fusion protein (NF-L–FP) in bacteria.
Crude extracts prepared from each expression system were
mixed together to allow binding between myosin Va and
NF-L, which were then immunoprecipitated with an anti-
body to either myosin Va–FP (anti–
 
 
 
-gal monoclonal anti-
body) or NF-L–FP (anti-Myc polyclonal antibody). The im-
munoprecipitates were separated on SDS-PAGE and blotted
onto nitrocellulose for Western blot analysis. Myosin Va–FP
and NF-L–FP were detected with a mixture of anti–
 
 
 
-gal
and anti–c-myc antibodies. Anti-Myc Ab (Fig. 3 B, lane 1)
or anti–
 
 
 
-gal Ab (Fig. 3 B, lane 4) immunoprecipitated
both myosin Va–FP and NF-L–FP. As expected, in un-
mixed bacterial extracts, Myc antibody immunoprecipitated
only NF-L–FP (Fig. 3 B, lane 2) but not myosin Va–FP
(Fig. 3 B, lane 3), whereas 
 
 
 
-gal antibody specifically precip-
itated myosin Va–FP (Fig. 3 B, lane 5) but not NF-L–FP
(Fig. 3 B, lane 6). In contrast to NF-L, bacterially expressed
NF-M or NF-H subunits alone did not coimmunoprecipi-
tate with myosin Va–FP (unpublished data).
Figure 3. Myosin Va binds only to NF-L subunit of the neurofilament 
triplet. (A) Equal amounts of purified neurofilament subunits (H, M, 
and L) were blotted onto membranes and incubated with different 
concentrations of recombinant myosin Va tagged with  -galactosidase 
(lane 2, 10  g; lane 3, 1  g; lane 4, 0.1  g; lane 5, 0.01  g; and lane 6, 
0  g). Binding of myosin Va to NF-L was detected with an anti– -gal 
antibody. Lane 1 is Coomassie blue staining of purified NF subunits. 
(B) Myosin Va and NF-L fusion proteins physically associate with each 
other in coimmunoprecipitation assays. Bacterial extracts containing 
either a myosin Va– -gal fusion protein (myosin Va–FP) or an 
NF-L–c-Myc fusion protein (NF-L–FP) were mixed together to allow 
binding. Resultant NF-L–FP–myosin Va complexes were precipitated 
with either an anti–c-myc polyclonal antisera or an anti–
 -galactosidase monoclonal antibody. Asterisks indicate nonspecific 
binding. (C) In vivo evidence for a physical interaction between NF-L 
and myosin Va. Triton-insoluble cytoskeleton preparations from 
brain and spinal cord at protein amounts of 0.6 mg (lane 4) and 1.2 mg 
(lanes 1 and 5) or 2.4 mg (lane 2) were immunoprecipitated with 
anti–NF-L antibody (NR-4). Lane 3 contained 2.4 mg of brain protein 
without antibody. The precipitates were immunoblotted with 
antibodies to myosin Va or NF-L (NR-4). The immunoprecipitates 
contained a strong immunoreactive myosin Va band at 190 kD on 
the gel and minor degraded forms.
Figure 2. Distribution of myosin Va immunoreactivity in CNS and 
PNS tissues. (A–C) Immunocytochemistry with myosin Va antibody 
reveals widespread labeling of neuronal populations and fiber tracts 
in cerebellum (A), cerebral peduncle (A, inset), spinal cord–
corticospinal tract (B), and sciatic nerve (C). Bar, 100  m. 
(D–J) Ultrastructural localization of myosin Va within axons of mouse 
brain and optic nerve. Immunogold electron microscope studies of 
optic nerve (D and E) with myosin Va antibody demonstrate that 
myosin Va heavily decorates neurofilaments in optic nerves of 
control mice (D) but not in dl mice (E), which lack myosin Va. In 
axons with fewer neurofilaments, myosin Va is localized to neuro-
filaments (F and G), and it is rarely associated with microtubules 
(see arrowheads). Myosin Va is also associated with profiles of 
smooth ER (H, large arrow), small intracellular vesicles (I, arrow), and 
mitochondria (J, large arrows). Bars: (D and E) 0.5  m; (F–J) 2  m.Myosin Va associates with the NF-L subunit of neurofilaments | Rao et al. 283
Interaction of endogenous myosin Va with NF-L
Because the NF-L subunit of the neurofilament triplet is the
prime ligand for myosin Va, it was of interest to determine
whether myosin Va would coimmunoprecipitate with NF-L
from neuronal tissue. Using the NF-L mAb NR-4 (Sigma-
Aldrich), we immunoprecipitated NF-L from Triton-insolu-
ble cytoskeletal preparations of brain and spinal cord and
observed that the immunoprecipitates were enriched not
only for NF-L (Fig. 3 C, bottom) but also for myosin Va
(top, lanes 1, 2, 4, and 5). In the absence of NF-L antibody,
no myosin Va or NF-L sedimented after centrifugation of
the Sepharose beads (lane 3), indicating that precipitation of
myosin Va and NF-L was antibody dependent.
Myosin Va binds selectively to IF proteins 
of several classes
The specificity of myosin Va binding to cytoskeletal proteins
was further investigated by blot overlay analysis of Triton-
insoluble cytoskeletal fractions from mouse spinal cord (Fig.
4 A, lanes 1–5) and sciatic nerve (Fig. 4 A, lanes 6–10). In
both tissues studied, the major binding partner of myosin
Va was NF-L (Fig. 4 B); however, we also observed binding
of myosin Va to a 45-kD protein in spinal cord (Fig. 4 A,
lanes 2–5) and to a 55-kD protein in sciatic nerve (Fig. 4 A,
lanes 6–9). Based on these apparent molecular masses on
SDS gels, we probed the same blots with antibodies to glial
fibrillary acidic protein (GFAP), a 45-kD protein (Fig. 4 D),
and peripherin (Fig. 4 C), a 55-kD protein, and observed
that the immunoreactivity of these proteins overlapped pre-
cisely with the positions of the protein bands detected by
myosin Va binding. Thus, from the dozens of different pro-
teins present in the cytoskeleton preparations, myosin Va
bound specifically to three structurally related IF proteins. It
is not surprising that actin was not detected in this overlay
assay because this myosin Va clone (Fb8; Engle and Ken-
nett, 1994) does not have a complete actin binding site.
Myosin Va levels in sciatic nerve are influenced 
by neurofilaments in vivo
Based on the foregoing evidence of a myosin Va–NF-L asso-
ciation, we next examined whether the levels of NF-L in ax-
ons influence the axonal content of myosin Va by analyzing
mice in which neurofilament levels were altered. Targeted
mice lacking the NF-L gene are devoid of NF-L and virtu-
ally all neurofilaments (Zhu et al., 1997). NF-L is absent in
Figure 4. Myosin Va selectively binds to IF proteins in blot overlay 
assays. Cytoskeletal preparations (lane 2, 158  g; lane 3, 100  g; 
lane 4, 50  g; lane 5, 25  g; lane 6, 100  g; lane 7, 50  g; lane 8, 
25  g; and lane 9, 12.5  g) from (A) spinal cord (lanes 1–5) and sciatic 
nerves (lanes 6–10) of C57BL/6J mice were fractionated on 7% 
polyacrylamide gels and transferred to membranes, and blot overlay 
assay was done with purified myosin Va–tagged protein, as indicated 
in Fig. 3 A. Myosin Va also bound to peripherin and GFAP. GFAP is 
present in spinal cord cytoskeletons (lanes 2–5) but not in sciatic 
nerves (lanes 6–9). Peripherin is expressed in sciatic nerve (lanes 6–9) 
but not in spinal cord. Lane 1, spinal cord; lane 10, sciatic nerve 
cytoskeletal proteins stained with Coomassie blue. The following 
panels were probed with the indicated antibody to show their 
identity: B, NF-L; C, peripherin; D, GFAP; and E, actin.
Figure 5. Myosin Va levels are modulated by NF-L expression in 
sciatic nerves. (A) Myosin Va levels are significantly lower in sciatic 
nerves from NF-L–deleted mice. Equal amounts of sciatic nerve 
cytoskeletal protein from wild-type (lane 1), NF-L–deleted (lane 2), 
and NF-H–deleted mice (lane 3) were immunoblotted with antibodies 
to either myosin Va or NF-L (NR-4). Quantitative results for the 
expression of myosin Va (B) and NF-L (C) in control mice (open bars); 
NF-L null (dotted bars) and NF-H null (striped bars) are also shown. 
In D, myosin Va levels are increased in sciatic nerves from NF-L–
overexpressing mice. Cytoskeleton fractions from sciatic nerves of 
wild-type (D, lane 1) and NF-L–overexpressing mice (D, lane 2) 
were immunoblotted as indicated in A. The quantitative values for 
the expression of myosin Va (E) or NF-L (F) in control (open bar) and 
NF-L transgenic mice (striped bar) are shown. Myosin Va and NF-L 
levels in NF-L transgenic mice are expressed relative to values for 
control mice.  -Tub,  -tubulin.284 The Journal of Cell Biology | Volume 159, Number 2, 2002
the sciatic nerves of these mice (Fig. 5, A and C, lane 2), and
we observed a 55% reduction in the levels of myosin Va
(Fig. 5, A and B, lane 2). By contrast, myosin Va levels were
not altered in sciatic nerves of NF-H–deleted mice (Fig. 5, A
and C, lane 3), in which NF-L and neurofilament levels in
axons are normal (Rao et al., 1998). The effects on myosin
Va of increasing NF-L levels and filament number in axons
were also examined in mice overexpressing the NF-L protein
(Xu et al., 1993). NF-L levels and neurofilament counts in
sciatic nerves from NF-L–overexpressing mice have been
previously shown to be  1.5-fold higher than the corre-
sponding control mice (Xu et al., 1993). We confirmed the
reported increase in NF-L levels (Fig. 5, D and F, lane 2)
and observed by quantitative immunoblot analyses that my-
osin Va levels were comparably increased (50%) in the sci-
atic nerves of NF-L transgenic mice (Fig. 5 D, lane 2). These
results indicate that axonal myosin Va content is influenced
by levels of NF-L, neurofilament number, or both.
In vivo axonal transport of myosin Va
In earlier studies, we tentatively identified a Triton-soluble
radiolabeled protein advancing 1–2 mm/d in the slow phase
of axonal transport as a form of myosin (Lewis and Nixon,
1988). This protein, however, comigrated on SDS gels with
multiple phosphovariants of NF-H, which precluded its full
characterization. To eliminate NF-H as a confounding vari-
able, we conducted the present myosin Va transport study in
NF-H–deleted mice (Rao et al., 1998). Retinal ganglion
cells of NF-H–deleted mice were labeled by intravitreous in-
jection of [
35S]methionine, and after 3 d, we prepared Tri-
ton-soluble and Triton-insoluble fractions from optic nerves
or optic tracts pooled from three mice and immunoprecipi-
tated myosin Va. Myosin Va coimmunoprecipitated with
only a limited set of labeled proteins, which included NF-L,
NF-M, spectrin (a known neurofilament binding protein;
Frappier et al., 1991), actin, as well as several unidentified
proteins (Fig. 6 A). The identities of immunoprecipitated
myosin Va, NF-L, and actin were confirmed by Western
blot analysis on the same blots after autoradiography (Fig. 6
C). No radiolabeled proteins were precipitated by preim-
mune IgG used under the same conditions before myosin
Va immunoprecipitation (unpublished data).
Most of the radiolabeled myosin Va was still present in
the optic nerve 3 d after isotope injection, indicating that
myosin Va principally moves in the slow phase of axonal
transport. To establish the transport pattern more precisely,
additional NF-H–null mice were injected intravitreously
with [
35S]methionine. After 3 or 7 d, the optic pathways
Figure 6. A pool of pulse-labeled myosin Va in optic axons is as-
sociated with the neurofilament cytoskeleton. Pulse-labeled NF-H–
deleted optic nerves (lanes 1 and 3) and optic tracts (lanes 2 and 4) 
were isolated and fractionated. (A) Triton-soluble (lanes 1 and 2) 
and -insoluble (lanes 3 and 4) fractions were immunoprecipitated 
with myosin Va antibody. The washed immunoprecipitates (A) and 
the corresponding “unprecipitated” supernatants (B) were separated 
on SDS gels, transferred to nitrocellulose membranes, and visualized 
by autoradiography. Blots from A were then probed with antibodies 
to myosin Va, NF-L, and actin to confirm the positions of these 
proteins on the gels. Note that absence of soluble NF-L explains the 
lack of immunostaining in immunoprecipitates of Triton-soluble 
fractions. Spect, spectrin.
Figure 7. Quantitative distribution of radiolabeled myosin Va, 
NF-L, and actin along optic axons at 3 and 7 d after synthesis. 
NF-H–null mice were used to determine the distribution of labeled 
Triton-soluble and -insoluble myosin Va in the optic axons. The optic 
pathways from multiple groups of three mice at 3 (A, C, E, G, and I) 
and 7 d (B, D, F, H, and J) after intravitreal injection of [
35S]methionine 
were cut into eight 1.1-mm segments at consecutive levels extending 
from the eye to the lateral geniculate body. Triton X-100–soluble 
and –insoluble fractions were subjected to SDS-PAGE, electroblotting, 
and autoradiography. The regions of the membrane containing labeled 
soluble (A and B) and insoluble (C and D) myosin Va, soluble (E and F) 
and insoluble (G and H) actin, and NF-L (I and J) were identified by 
immunoblotting, and the corresponding radiolabeled bands were 
quantified by laser densitometry and plotted against optic pathway 
nerve segments numbered consecutively from the level of the eye. 
Each point is the mean   SD for an average of six independent 
experiments. Note that the error bars for some values are too small 
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from three mice were then cut into eight consecutive 1.1-
mm segments, which were fractionated into Triton-soluble
and -insoluble fractions and subjected to electrophoresis,
electroblotting, and autoradiography. The myosin Va in
Triton-soluble (Fig. 7, A and B) and cytoskeleton-associated
fractions (Fig. 7, C and D) displayed a similar transport pat-
tern, moving as a wave averaging 0.73–0.94 mm/d (peak) to
2.2 mm/d (front), which correspond to a typical slow com-
ponent b rate of transport (0.8–2 mm/d) in optic axons
(Nixon, 1991).
Triton-soluble actin displayed a transport profile (Fig. 7
E) similar to that of myosin Va. Cytoskeleton-associated ac-
tin also moved into optic axons at a rate of 1.1 mm/d (Fig. 7
G) (Yuan et al., 2000), but a significant proportion of this
insoluble actin slowed to a rate similar to that of NF-L (Fig.
7 I, 0.31 mm/day). The slower movement of neurofilaments
than much of its associated protein myosin Va suggests a dy-
namic association during axonal transport, which is not un-
expected in light of observations that microtubule-associated
proteins, the family of proteins that associate with microtu-
bules in axons, are also transported more rapidly than tubu-
lins in vivo (Nixon et al., 1990; Mercken et al., 1995).
Neurofilament depletion alters the transport and 
distribution of myosin Va in axons
Direct evidence for an in vivo interaction of myosin Va with
NF-L was sought by investigating whether the elimination
of neurofilaments altered the movement or principal loca-
tion of myosin Va in axons. To visualize radiolabeled myo-
sin Va on gels in pulse-labeling studies, we analyzed axonal
transport patterns in optic nerves of mice deleted of both
NF-L and NF-H. In these neurofilament-deficient axons,
the average rate of myosin Va translocation was significantly
faster than that in normal axons at 3 or 7 d after [
35S]me-
thionine injection (Fig. 8, A and B). Transport of tubulin
and major slow component b proteins was unaltered in neu-
rofilament-deficient mice (Fig. 8, E and F). Immunogold la-
beling NF-L-null mice showed that, in the absence of neu-
rofilaments, myosin Va distribution is restricted to the
subaxolemmal compartment and to the surfaces of membra-
nous vesicles (Fig. 8, G and H). An increased incidence of
subaxolemmal labeling implied that a proportion of the neu-
rofilament-associated myosin Va was redistributed in these
mice. These observations demonstrate unequivocally that a
significant proportion of myosin Va normally interacts with
neurofilaments in vivo.
Neurofilament number and density 
are increased in mice lacking myosin Va
To further establish the physiological significance of the my-
osin Va–neurofilament interaction, we analyzed the ultra-
structure and cytoskeletal protein content of peripheral
nerves from dilute mice and their normal littermates. Neu-
rofilament number was increased nearly twofold (P  
0.001) in axons of dl mice compared with littermate con-
trols (mean   SEM, 1177   105 vs. 666   51 NFs/axon,
respectively [n   75–85 axons]). Regression analyses indi-
cate that the density of neurofilaments was also significantly
higher (P   0.0001) in axons of all caliber sizes in the dilute
mice (251   13 vs. 113   7 NF/ m
2) (Fig. 9, A and C, in-
set). Western blot analyses confirmed an increased content
of NF-L of  60% in dl sciatic nerves compared with con-
trols (Fig. 9 E). By contrast, levels of  III-tubulin and actin
in the same nerve extracts were not significantly altered by
deletion of myosin Va. The distribution of axon cross-sec-
tional areas in dilute mice was similar to control mice, indi-
cating that the higher neurofilament densities did not alter
axonal calibers (Fig. 9 D). Coupled with the analyses of NF-
L–null and transgenic mice (Fig. 5), these studies provide
strong evidence for a physiological interaction between myo-
sin Va and neurofilaments, which modulates neurofilament
organization in axons.
Discussion
Our results identify the molecular motor, myosin Va, as a
neurofilament-associated protein and establish NF-L as a
Figure 8. Axonal transport and distribution of myosin Va along 
optic axons of mice lacking neurofilaments. Accelerated axonal 
transport of radiolabeled myosin Va (A–D), but not tubulin (E) or a 
170-kD protein (F) in slow component b, and redistribution of myosin 
Va (G and H) along optic axons of mice lacking neurofilaments. The 
optic pathways were dissected from multiple groups of three wild-type 
(WT) or NF-H/NF-L double null (HL-DKO) mice at 3 and 7 d after 
intravitreal injection of [
35S]methionine and analyzed, as indicated 
in Fig. 7. (G and H) Immunogold electron microscopy with myosin 
Va antibody reveals in optic axons of NF-L–null mice no immuno-
labeling of microtubules and core axoplasm. Myosin Va labeling is 
restricted to the subaxolemmal compartment (G and H, thin arrows) 
and membranous organelles (G, thick arrow). Note that the myelin 
sheaths are negatively stained in these images.286 The Journal of Cell Biology | Volume 159, Number 2, 2002
major ligand of myosin Va in nervous tissue. Multiple lines
of evidence support these conclusions. First, more than half
of the total myosin Va in CNS tissues coisolates with the
neurofilament-rich Triton-insoluble cytoskeleton. Second,
immunoreactive myosin Va is abundant in nerve fiber tracts
of brain, spinal cord, and peripheral nerves. Immunoelec-
tron microscopic analyses show that the majority of the my-
osin Va in axons is associated with neurofilaments. Third,
electroblot overlay analyses and in vitro and in vivo coim-
munoprecipitation studies with either myosin Va or NF-L
antibodies establish that the binding of myosin Va to neu-
rofilaments is mediated through a specific association of my-
osin Va with the NF-L subunit. Fourth, we demonstrate in
vivo that myosin Va levels, distribution, and transport in ax-
ons are influenced by the level of NF-L subunits. Finally, de-
letion of the myosin Va gene in dilute mice selectively alters
neurofilament content and organization in axons.
In addition to establishing a novel myosin Va–neurofila-
ment association, our results confirm previously observed as-
sociations of myosin Va with ER membranes, synaptic vesi-
cles (Tabb et al., 1998), and actin. Extending observations
that myosin Va is an actin binding protein (Espreafico et al.,
1992; Cheney et al., 1993), we demonstrated that in vivo–
labeled actin and myosin Va coimmunoprecipitate and
cotransport and that myosin Va antibodies decorate the ac-
tin-rich subaxolemmal compartment (Fig. 2; Fig. 8, G and
H; Kobayashi et al., 1986). It is not surprising that the myo-
sin Va–neurofilament interaction has been less well appreci-
ated than the associations of myosin Va with actin or mem-
branous organelles because previous myosin Va localization
studies have focused on organelle-rich and neurofilament-
poor cellular compartments in cell bodies and dendrites in
brain, rather than in axons.
The NF-L subunit is one of only a limited number of pro-
teins that interacts directly with myosin Va. The further ob-
servation that the two other major ligands in the spinal cord
and sciatic nerve are also IF proteins, GFAP and peripherin,
suggests that myosin Va plays a more general role in IF be-
havior or that IFs mediate important functions of myosin
Va. By performing multiple protein sequence alignment
with hierarchical clustering (Corpet, 1988; Multalin version
5.4.1) on NF-L, peripherin, and GFAP, we found 132
amino acid homologies in a sequence of 350 residues corre-
sponding to the head and rod domains. The observation
that as many as 82 of these amino acid positions differ in
NF-H and NF-M may partly explain the relative selectivity
of the myosin Va binding to the three “core” subunits of IFs.
The observation that other high abundance proteins, such as
tubulin, bound negligible amounts of myosin Va under-
scores the specificity of the myosin Va–IF interaction. More-
over, that another molecular motor, kinesin, is found in neg-
ligible amounts in cytoskeletal fractions indicates that tight
association with cytoskeletal structures is not a general fea-
ture of motor molecules.
The association of myosin Va with neurofilaments raises
new possibilities regarding its function in the nervous system
Figure 9.  Increased neurofilament content and 
density in dl axons. Neurofilament profiles 
counted in each of 160 axons from two 27-d-old 
dl ( ) and two littermate controls ( ) were
regressed against axonal cross-sectional areas (A), 
revealing a significantly increased neurofilament 
density in dl mice (P   0.0001, Mann-Whitney 
test). The general organization of axoplasm in dl 
mice (B) was similar to that in normal mice (C), 
but neurofilament numbers are increased (insets). 
(D) The distribution of cross-sectional areas of the 
entire fiber population of the sciatic nerves from 
the four mice analyzed in A. Mean cross-sectional areas ( SEM) are indicated. In E, equal amounts of cytoskeletal (Cyto.) and Triton-soluble 
(Sol.) fractions from control (Con) and dl (Dil) mice were immunoblotted with the antibodies against myosin Va (pMyo Va), NF-L (NR-4), 
neuron-specific  III-tubulin (T-8660), and actin (A-2066).Myosin Va associates with the NF-L subunit of neurofilaments | Rao et al. 287
where levels are exceptionally high (Cheney et al., 1993).
One of these possibilities is modulating the organization of
the axoplasm. We observed that myosin Va deletion in dilute
mice creates a denser packing of neurofilaments in axons,
suggesting a role in neurofilament spacing. Because NF-L
and actin bind to myosin Va at separate sites, myosin Va
may be capable of dynamically cross-linking IFs and mi-
crofilaments. Recent studies have emphasized the role of
molecules other than neurofilaments themselves in regulat-
ing lateral spacing of filaments in axons. Molecules, includ-
ing BPAG and plectin, have recently been shown to cross-
link IFs, microfilaments, and microtubules (Svitkina et al.,
1996; Yang et al., 1996), although, unlike myosin Va, these
proteins have no known ATPase or motor activity. If myosin
Va does in fact link filament systems, it is likely to be in the
service of dynamically rearranging these structures within
the cytoskeletal network. Neurofilaments could either act as
an anchor from which myosin Va could move other proteins
or vesicular organelles (e.g., actin) or as a cargo of myosin
Va. In regard to the first possibility, neurofilaments provide
a three-dimensional lattice interconnecting the microtubule
system with the subaxolemmal compartment (Yang et al.,
1996). This stationary network of filaments conceivably
could represent a system of tracks well suited for myosin Va
to guide microfilaments or membranous organelles laterally
within axons to achieve the proper radial organization of
these structures. Neurofilaments have also been shown to be
possible ligands of membrane-associated enzymes and recep-
tors (Terry-Lorenzo et al., 2000; Kim et al., 2002), raising
the possibility that movements of molecules of this type
along neurofilaments may be mediated by myosin Va. Myo-
sin Va has been implicated in moving actin short distances
within growth cones (Evans et al., 1997; Bridgman, 1999;
Huang et al., 1999). Finally, short-range rearrangements of
neurofilaments within the axon, such as those that occur
during early postnatal development (Sanchez et al., 1996),
might also require motor activity.
Actin and neurofilaments also move long distances by
slow axonal transport. The average rate of myosin Va trans-
port that we observed along optic axons is similar to that of
actin and close to the rate at which purified myosin Va
moves along actin cables from dissected Nitella cells in vitro
(2.5–3.8 mm/d) (Cheney et al., 1993). Interestingly, Wil-
lard (1977) identified two polypeptides (195 kD and 200
kD) that cosediment with actin in an ATP-reversible way
and were transported along optic axons at slow transport
rates. Transport of at least some neurofilaments in growing
axons of cultured neurons involves a series of rapid move-
ments punctuated by long periods of immobility (Wang et
al., 2000). This pattern suggests that motors, such as kine-
sin, which are capable of mediating fast transport rates, may
be attractive candidates for powering neurofilament move-
ment. Because myosin Va can bind directly to kinesin
(Huang et al., 1999), the interaction of myosin Va with neu-
rofilaments could represent one mechanism to facilitate neu-
rofilament movement along microtubules. Although the re-
sults in dilute mice imply that myosin Va is not essential for
movement of neurofilaments into axons, the considerably
increased neurofilament number in axons could reflect im-
paired slow transport. However, a particular pattern of neu-
rofilament distribution along axons, by itself, is not predic-
tive of transport kinetics. An increased rate of incorporation
of transported neurofilaments into the stationary cytoskele-
tal network along axons (Nixon, 1998) would yield a similar
picture. Definitive tests of these possibilities require long-
term labeling studies that are precluded in dilute mice by the
frailty and early death of these mice after 3–4 wk.
In conclusion, these novel interactions of myosin Va with
IFs indicate previously unrecognized roles for myosin Va in
regulating cytoskeleton dynamics in the nervous system. Al-
though long or short range transport and/or rearrangements
of neurofilaments represent several of the possible roles, in-
teractions between neurofilaments and myosin Va might in-
stead, or in addition, be important in modulating myosin
Va–mediated movements of other cytoskeletal proteins,
membranous organelles, or membrane-associated proteins.
A variety of experimental approaches will be required to in-
vestigate the range of intriguing possibilities.
Materials and methods
Animals and dissections of tissue
Control mice were the normal mouse strain C57BL/6J. Brain, spinal cord,
sciatic, and optic nerves from 4-mo-old mice were dissected as previously
described (Nixon and Logvinenko, 1986). NF-L–null mice were screened
according to Zhu et al. (1997). NF-L Tg mice were screened according to
Xu et al. (1993). NF-H–deleted mice were screened according to Rao et al.
(1998). NF-H/NF-L double knockout mice (HL-DKO) were generated by
crossbreeding and screening according to Rao et al. (1998) and Zhu et al.
(1997). Dilute mice were bought from Jackson ImmunoResearch Laborato-
ries. All the tissues were frozen on dry ice and stored at  80 C. To extend
survival of dl mutants to 4 wk, pups were fed manually every 8 h from
postnatal day 10 with kitten formula (KMR; PetAg Inc.) dissolved in sterile
water and mixed with maize syrup.
Protein isolation, Western blot analysis, and densitometry
Total protein homogenates from brain, spinal cord, sciatic, and optic
nerves were made according to Rao et al. (1998). Protein concentration
was determined using bicinchoninic acid (BCA) assay kit (Pierce Chemical
Co.). Protein extracts of known amounts from different neuronal tissues
were fractionated on SDS-PAGE gels containing 6 or 7.5% polyacrylamide
and transferred to nitrocellulose membranes. Triton-insoluble and -soluble
fractions were made according to Nixon et al. (1990). After protein estima-
tion, equal amounts of Triton-insoluble and -soluble fractions were boiled,
run on a 7% SDS–polyacrylamide gel, and immunoblotted with affinity-
purified polyclonal antibody directed against the COOH terminus of the
myosin Va fusion protein (Evans et al., 1997), NF-L (NR-4),  -tubulin
(DMIA), and kinesin heavy chain mAbs as specified by the manufacturer.
The blots were processed with the ECL system (Amersham Biosciences) or
the alkaline phosphatase system (Promega). Band images were quantified
with a BioImage whole band analyzer from Kodak.
Immunocytochemistry of mouse tissues
C57BL/6J mice were anesthetized and fixed by cardiac perfusion using
10% neutral buffered formalin in TBS, pH 7.4. The brain, cervical spinal
cord, and sciatic nerves were dissected and 40- m-thick vibratome sec-
tions were processed for immunocytochemistry (Cataldo et al., 1990) us-
ing a polyclonal antibody directed against myosin Va. Several sections
were processed in tandem in the absence of primary antibody and served
as controls.
Immunoelectron microscopy and morphometry of optic and 
sciatic nerves
3–4-wk-old dl and their control mice and NF-L–null mice were anesthe-
tized and perfused fixed with 4% paraformaldehyde–0.2% glutaraldehyde
in 0.1 M cacodylate buffer (pH 7.4). The tissues were fixed for an addi-
tional 2 h at room temperature in 10% formalin. The brain and optic path-
way were removed and 40- m-thick vibratome sections of the cerebral
peduncle and the optic pathway at a distance of 700  m from the retina
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described (DeMey, 1983). Ultrathin sections were placed on nickel-coated
grids and processed for postembedding immunostaining (DeMey, 1983)
using a polyclonal antibody directed against myosin Va. Grids incubated
without primary antibody served as controls. All grids were poststained in
uranyl acetate and lead citrate and inspected using a JEOL 100EX electron
microscope.
Sciatic nerves were dissected and analyzed morphometrically to deter-
mine axonal cross-sectional areas for the entire fiber population and neu-
rofilament numbers for a representative subpopulation of axons, as previ-
ously described (Rao et al., 1998).
Blot overlay binding assay
Neurofilament triplet subunits were purified as previously reported (Balin
et al., 1991). The myosin Va fusion protein ( 120 kD) (Engle and Kennett,
1994) consists of a small 3.5-kD piece of  -galactosidase fused to that por-
tion of myosin Va representing 57% of the full-length protein containing
half of the actin binding site, calmodulin binding domains,   helical
coiled-coil domains, and a small portion of the COOH-terminal tail do-
main. The fusion protein was expressed in XL-1 Blue Escherichia coli (Strat-
agene) cells and purified using an anti– -galactosidase affinity column
(Promega) per the manufacturer’s protocol. 10  g of purified neurofila-
ment triplet proteins were run per lane on a 7% SDS–polyacrylamide gel,
blotted onto nitrocellulose, and cut into strips. The strips were blocked and
incubated in 10  g/ml, 1  g/ml, 0.1  g/ml, 0.01  g/ml, or, as a control, 0
 g/ml of myosin Va fusion protein in PBS. Bound myosin Va– -gal was
detected with anti– -galactosidase mAb (Boehringer) according to the
manufacturer’s instructions and blots were processed with the ECL system
(Amersham Biosciences) and by exposure to Kodak XAR film. The purified
neurofilament triplet proteins immobilized on the nitrocellulose were visu-
alized by Coomassie blue staining. Cytoskeletal blot overlay assays were
performed same as indicated above for purified NF proteins.
Coimmunoprecipitation of myosin Va and NF-L fusion proteins
Myosin Va– -gal fusion protein was expressed as described above and the
crude extract was used for immunoprecipitation. NF-L myc-tagged plas-
mid (Heins et al., 1993) was transfected into BL21-DE3 host cells, induced,
NF-L–containing lysates were made, and protein concentrations deter-
mined. 2  g of NF-L–FP crude extract and myosin V–FP crude extract
(containing  3  g of myosin Va–FP) were mixed together in 1  RIPA
buffer. Protein A/G–agarose (Boehringer) was also added to preclear. The
mixture was incubated overnight at 4 C to allow binding between NF-L–FP
and myosin Va–FP. As controls, 2  g of NF-L–FP or 3  g of myosin Va–FP,
in 1  RIPA buffer were also precleared with protein A/G–agarose over-
night at 4 C. Protein A/G–agarose was removed with centrifugation, and
NF-L–FP/myosin Va–FP complex, NF-L–FP alone, and myosin Va–FP alone
were immunoprecipitated for 8 h at 4 C with either 5  l of a polyclonal
Myc antisera (to precipitate NF-L–FP) or with 2.5  l of 1:300 dilution of
anti– -galactosidase mAb (Promega). Protein G–agarose (50  l) was
added and the mixtures were nutated overnight at 4 C. Protein G–agarose
was pelleted, washed, boiled in Laemmli buffer, fractionated on 7.5%
SDS–polyacrylamide gels, blotted onto nitrocellulose membranes, and
probed with a mixture of anti– -gal and anti-Myc antisera.
Immunoprecipitation of myosin Va with NF-L antibody
Triton X-100–insoluble fractions were suspended in TBS, and SDS was
added to a final concentration of 1%. The samples were diluted 1:4 in neu-
rofilament extraction buffer (60 mM Tris-HCl, pH 7.4, 190 mM NaCl, 6
mM EDTA, 1.25% Triton X-100, 1 mM PMSF). The samples were soni-
cated for 20 s and protein was estimated by bicinchoninic acid (BCA)
method. A monoclonal antibody to NF-L (NR-4) was added to 0.6–2.4 mg
of cytoskeletal fractions at a dilution of 1:10 and the samples were incu-
bated overnight at 4 C. The antigen antibody complex was precipitated us-
ing protein A/G–Sepharose (Santa Cruz Biotechnology, Inc.), washed,
boiled in Laemmli buffer, fractionated on 7% SDS gels, and immunoblot-
ted with myosin Va and NF-L antibodies.
Immunoprecipitation of 
35S-labeled myosin Va
NF-H–null mice were injected intravitreally with 100  Ci of [
35S]methio-
nine into each eye and killed after 3 d, as previously described (Nixon and
Logvinenko, 1986). Cytosolic and cytoskeletal fractions of optic nerves
and tracts obtained were used to immunoprecipitate labeled myosin Va
using an affinity-purified polyclonal antibody to myosin Va (Evans et al.,
1997). The samples were incubated overnight at 4 C. The antigen–anti-
body complex was precipitated using protein A/G–Sepharose, electro-
phoresed, electroblotted, and exposed to X-ray film followed by Western
blotting for myosin Va, NF-L, and actin.
Slow axonal transport of pulse-labeled myosin Va and 
neurofilaments in optic axons
The retinal ganglion cells of 3–4-mo-old NF-H and NF-H/NF-L double null
mice were radiolabeled in vivo with 100  Ci of [
35S]methionine by intra-
vitreal injection. 3 and 7 d after injection, optic pathways from groups of
three animals were cut into eight consecutive 1.1-mm segments. Triton-
soluble and -insoluble NF-rich cytoskeleton preparations from each seg-
ment were subjected to SDS-PAGE, electrotransfer of proteins, phosphor-
imaging, and autoradiography.
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